Unichem Labs gets USFDA nod to Cyclobenzaprine Hydrochloride Tablets to treat muscle spasm
Cyclobenzaprine HCl Tablets are indicated for the treatment as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.
Mumbai: Unichem Laboratories Limited has received ANDA approval for its Cyclobenzaprine Hydrochloride Tablets USP, 5 mg, 7.5 mg and 10 mg from the United States Food and Drug Administration (USFDA) to market a generic version of FLEXERIL® (Cyclobenzaprine HCl) Tablets, 5 mg and 10 mg of Janssen Research and Development LLC.Cyclobenzaprine HCl Tablets are indicated for the treatment as an...
Mumbai: Unichem Laboratories Limited has received ANDA approval for its Cyclobenzaprine Hydrochloride Tablets USP, 5 mg, 7.5 mg and 10 mg from the United States Food and Drug Administration (USFDA) to market a generic version of FLEXERIL® (Cyclobenzaprine HCl) Tablets, 5 mg and 10 mg of Janssen Research and Development LLC.
Cyclobenzaprine HCl Tablets are indicated for the treatment as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. The product will be commercialized from Unichem's Goa plant.
Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.
Read also: Unichem Labs gets USFDA EIR for Roha API facility
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd